Charity Nofziger

Dr. Charity Nofziger

1. Pharmgenetix GmbH, A-5081 Niederalm, Austria</br> 2. Research Associate at the Institute for Pharmacology and Toxicology, Paracelsus Private Medical University of Salzburg, Salzburg, Austria
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CNCharity Nofziger
Charity Nofziger
ATAmy J. Turner
Amy J. Turner
KSKatrin Sangkuhl
Katrin Sangkuhl
MWMichelle Whirl-Carrillo
Michelle Whirl-Carrillo
Jose AgundezJose Agundez
Jose Agundez
AGAndrea Gaedigk
Andrea Gaedigk
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism of numerous drugs and, thus, can impact drug efficacy and safety. This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).

25 November 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Alejandra PeraAlejandra Pera
Alejandra Pera
Silvia DossenaSilvia Dossena
Silvia Dossena
SRSimona Rodighiero
Simona Rodighiero
MGMarta Gandía
Marta Gandía
GBGuido Bottà
Guido Bottà
MPMarkus Paulmichl
Markus Paulmichl
Pendred syndrome is an autosomal recessive disorder characterized by sensorineural hearing loss, with malformations of the inner ear, ranging from enlarged vestibular aqueduct (EVA) to Mondini malformation, and deficient iodide organification in the thyroid gland. Nonsyndromic EVA (ns-EVA) is a separate type of sensorineural hearing loss showing normal thyroid function. Both Pendred syndrome and ns-EVA seem to be linked to the malfunction of pendrin (SLC26A4), a membrane transporter able to exchange anions between the cytosol and extracellular fluid. In the past, the pathogenicity of SLC26A4 missense mutations were assumed if the mutations fulfilled two criteria: low incidence of the mutation in the control population and substitution of evolutionary conserved amino acids. Here we show that these criteria are insufficient to make meaningful predictions about the effect of these SLC26A4 variants on the pendrin-induced ion transport. Furthermore, we functionally characterized 10 missense mutations within the SLC26A4 ORF, and consistently found that on the protein level, an addition or omission of a proline or a charged amino acid in the SLC26A4 sequence is detrimental to its function. These types of changes may be adequate for predicting SLC26A4 functionality in the absence of direct functional tests.

1 June 2015 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
SSSelma M. Soyal
Selma M. Soyal
CNCharity Nofziger
Charity Nofziger
Silvia DossenaSilvia Dossena
Silvia Dossena
MPMarkus Paulmichl
Markus Paulmichl
WPWolfgang Patsch
Wolfgang Patsch

15 April 2009 in Journal of Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
Silvia DossenaSilvia Dossena
Silvia Dossena
SRSimona Rodighiero
Simona Rodighiero
VVValeria Vezzoli
Valeria Vezzoli
CNCharity Nofziger
Charity Nofziger
ESElisabetta Salvioni
Elisabetta Salvioni
MPMarkus Paulmichl
Markus Paulmichl
Pendred syndrome (PS) is the most frequent form of genetically related syndromic hearing loss, and is associated with mutations of pendrin, encoded by the SLC26A4 gene. This protein localizes to the cellular membrane and permits the exchange of anions between the cytosol and extracellular space. In the inner ear, pendrin conditions the endolymph, allowing for the proper function of sensory cells. Understanding the relationship between the genotype and phenotype of pendrin mutations would aid clinicians to better serve PS patients–however, little is known. Here, we summarize the available data concerning SLC26A4 mutations and how they relate to transporter function. The main findings suggest that all the truncation mutations tested annihilate pendrin function, and that the addition or omission of proline, or the addition or omission of charged amino acids in the sequence of SLC26A4 result in a substantial to dramatic reduction in pendrin function.

1 July 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
ADAmiel Dror
Amiel Dror
YPYael Politi
Yael Politi
HSHashem Shahin
Hashem Shahin
DLDanielle R. Lenz
Danielle R. Lenz
Silvia DossenaSilvia Dossena
Silvia Dossena
KAKaren B. Avraham
Karen B. Avraham
Calcium oxalate stone formation occurs under pathological conditions and accounts for more than 80% of all types of kidney stones. In the current study, we show for the first time that calcium oxalate stones are formed in the mouse inner ear of a genetic model for hearing loss and vestibular dysfunction in humans. The vestibular system within the inner ear is dependent on extracellular tiny calcium carbonate minerals for proper function. Thousands of these biominerals, known as otoconia, are associated with the utricle and saccule sensory maculae and are vital for mechanical stimulation of the sensory hair cells. We show that a missense mutation within the Slc26a4 gene abolishes the transport activity of its encoded protein, pendrin. As a consequence, dramatic changes in mineral composition, size, and shape occur within the utricle and saccule in a differential manner. Although abnormal giant carbonate minerals reside in the utricle at all ages, in the saccule, a gradual change in mineral composition leads to a formation of calcium oxalate in adult mice. By combining imaging and spectroscopy tools, we determined the profile of mineral composition and morphology at different time points. We propose a novel mechanism for the accumulation and aggregation of oxalate crystals in the inner ear.

28 September 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ATAmy J. Turner
Amy J. Turner
CNCharity Nofziger
Charity Nofziger
BRBronwyn E. Ramey
Bronwyn E. Ramey
RLReynold C. Ly
Reynold C. Ly
CBChad Bousman
Chad Bousman
AGAndrea Gaedigk
Andrea Gaedigk